Page last updated: 2024-12-06

butylhydroxybutylnitrosamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Butylhydroxybutylnitrosamine: A substituted carcinogenic nitrosamine. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

N-butyl-N-(4-hydroxybutyl)nitrosamine : A nitrosamine that has butyl and 4-hydroxybutyl substituents. In mice, it causes high-grade, invasive cancers in the urinary bladder, but not in any other tissues. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID19665
CHEMBL ID164923
CHEBI ID91275
SCHEMBL ID870314
MeSH IDM0003106

Synonyms (51)

Synonym
1-butanol, 4-(butylnitrosoamino)-
1-butanol, 4-(butylnitrosamino)-
n-butyl-n-(4-hydroxybutyl)nitrosamine
4-[butyl(nitroso)amino]butan-1-ol
3817-11-6
brn 2080574
n-nitroso-n-butyl-(4-hydroxybutyl)amine
dibutylamine, 4-hydroxy-n-nitroso-
n-nitrosobutylbutanolamine
4-hydroxybutylbutylnitrosamine
butyl-butanol-nitrosamine
n-nitroso-n-butyl-n-(4-carboxypropyl)amine
butanol (4)-butyl-nitrosamine
4-(n-butylnitrosamino)-1-butanol
n-butyl-(4-hydroxybutyl)nitrosamine
butylhydroxybutylnitrosamine
butyl-butanol(4)-nitrosamin [german]
4-(butylnitrosamino)-1-butanol
ccris 836
butylbutanolnitrosamine
n-butyl-n-butan-4-ol-nitrosamine
B0938
n-butyl-n-nitroso-4-aminobutanol
n-butyl-n-(4-hydroxybutyl)nitrous amide
FT-0690989
CHEMBL164923
dtxcid40210
tox21_301263
dtxsid2020210 ,
cas-3817-11-6
NCGC00255256-01
butyl-n-(4-hydroxybutyl)nitrosamine
AKOS015995017
4-(butylnitrosoamino)butanol
butyl-butanol(4)-nitrosamin
SCHEMBL870314
4-(butyl(nitroso)amino)butan-1-ol
CHEBI:91275
n-n-butyl-n-butan-4-ol-nitrosamine
4-(1-butyl-2-oxohydrazino)-1-butanol #
butyl(4-hydroxybutyl)nitrosamine
DIKPQFXYECAYPC-UHFFFAOYSA-N
4-hydroxybutyl butyl nitrosamine
J-513677
CS-D0403
Q26840775
EN300-7401472
bbn, oh-bbn
4-(butylnitrosoamino)-1-butanol
R2748J2P6S
butyl-n-(4-hydroxybutyl)nitrosamine, n-

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Nanocarriers may be a promising alternative for prolonged, effective and safe intravesical drug delivery due to their favorable size, surface properties and optimum interaction with mucosal layer of the bladder wall."( Cationic core-shell nanoparticles for intravesical chemotherapy in tumor-induced rat model: safety and efficacy.
Bilensoy, E; Erdogar, N; Eroglu, H; İskit, AB; Mungan, NA; Sargon, MF, 2014
)
0.4
" However, they have significant adverse cardiovascular effects."( Prevention of chemically induced urinary bladder cancers by naproxen: protocols to reduce gastric toxicity in humans do not alter preventive efficacy.
Bode, A; Boring, DL; Grubbs, CJ; Juliana, MM; Lubet, RA; Minasian, L; Scheiman, JM; Steele, VE; White, J, 2015
)
0.42

Pharmacokinetics

ExcerptReferenceRelevance
" NB4HBA half-life was 8 min, total body clearance and renal clearance were 86."( Pharmacokinetic profile and metabolism of N-nitrosobutyl-(4-hydroxybutyl)amine in rats.
Airoldi, L; Bonati, M; Bonfanti, M; Fanelli, R; Magagnotti, C, 1988
)
0.27

Compound-Compound Interactions

ExcerptReferenceRelevance
" Based on these findings combined with the previous study (part I), HBO treatment associated with ACNU might be available for the treatment of some cases of bladder tumors."( Hyperbaric oxygenation for experimental bladder tumor. II. Hyperbaric oxygenation in combination with chemotherapy in N-butyl-N-(4-hydroxybutyl)nitrosamine-induced bladder tumors.
Akiya, T; Chikenji, M; Katayama, T; Matsushita, T; Nakada, T; Ota, K; Saito, H, 1988
)
0.27
" The difference between the effect of MMC alone and that of MMC given in combination with Ro 10-9359 was not statistically significant."( Therapeutic effect of a retinoid (Ro 10-9359) on rats with bladder tumours induced by N-butyl-N-(4-hydroxybutyl)-nitrosamine upon administration alone or in combination with mitomycin C.
Fujita, J; Ito, Y; Tokuda, H; Yoshida, O, 1983
)
0.27
" The results indicate that this drug combination has no statistical significance on the development of pre-neoplastic urothelial lesions and had only a minor impact on invasive bladder cancer incidence in mice."( Experimental study of the anticancer effect of gemcitabine combined with sirolimus on chemically induced urothelial lesions.
Colaço, A; Lopes, C; Oliveira, PA; Palomino, LF; Santos, L; Vala, H; Vasconcelos-Nóbrega, C, 2011
)
0.37

Bioavailability

ExcerptReferenceRelevance
" dose, indicating high bioavailability and rapid urinary excretion."( Inhibition of urinary bladder carcinogenesis by broccoli sprouts.
Davis, W; Fahey, JW; Lister, C; Mhawech-Fauceglia, P; Munday, CM; Munday, JS; Munday, R; Paonessa, JD; Tang, L; Wilson, P; Zhang, Y, 2008
)
0.35

Dosage Studied

ExcerptRelevanceReference
" The results obtained indicate that time of onset of stimulated DNA synthesis related to carcinogen dosing is the decisive factor in modifying urothelial carcinogenesis in the proliferating urinary bladder."( Development of N-butyl-N-(hydroxybutyl)-nitrosamine-induced tumors in the partially resected, proliferating rat urinary bladder in dependence upon the time of onset of stimulated DNA synthesis.
Könnecke, B; Kunze, E; Nienaber, C, 1990
)
0.28
" The following 13 agents were evaluated; adriamycin (ADM), mitomycin-C (MMC), cyclophosphamide (CPM), 5-fluoro-uracil (5-Fu), N-(2-tetrahydrofuryl)-5-fluorouracil (FT-207), neocarcinostatine (NCS), carbazil quinone (CQ), bleomycin (BLM), vincristine (VCR) and cis-diammine-dichloroplatinum (CDDP) were dosed intraperitoneally, and N-(2-tetrahydrofuryl)-5-fluorouracil (FT-207), 1: 4 mixture of FT-207 and uracil (UFT) and 1-Hexylcarbamoyl-5-fluorouracil (HCFU) were dosed orally."( [Experimental model of urinary bladder tumor in rats for evaluation of chemotherapeutic agents].
Babaya, K; Hirao, Y; Momose, H; Okajima, E; Ozono, S; Samma, S, 1988
)
0.27
" H2O required to alter urinary or bladder mineral concentrations or the dose-response to NTA."( Effect of N-nitroso-n-butyl-(4-hydroxybutyl)amine exposure on the changes in mineral disposition caused by trisodium nitrilotriacetate.
Anderson, RL; Francis, WR; Kanerva, RL; Lefever, FR, 1986
)
0.27
"A dose-response study was carried out in male F344 rats with a specific urinary bladder carcinogen, N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN), which was administered as a solution in drinking water for up to 112 weeks."( Dose-response study of urinary bladder carcinogenesis in rats by N-butyl-N-(4-hydroxybutyl)nitrosamine.
Fukushima, S; Hirose, M; Ito, N; Shirai, T, 1984
)
0.27
" None of the incidences or numbers of these lesions were significantly different in any of the other saccharin-treated groups when compared to the group treated with BBN alone except for the incidences of two types of hyperplasias in the female rats dosed with 10,000 ppm saccharin."( Dose response of saccharin in induction of urinary bladder hyperplasias in Fischer 344 rats pretreated with N-butyl-N-(4-hydroxybutyl)nitrosamine.
Hagiwara, A; Imaida, K; Ito, N; Nakanishi, K; Shibata, M; Tatematsu, M, 1980
)
0.26
" These results suggest that there is a correlation between dose and induction time, but further dose-response studies are required."( Urinary bladder tumors induced by N-butyl-N-(4-hydroxybutyl)nitrosamine in dogs.
Babaya, K; Hijioka, T; Hiramatsu, T; Hirao, K; Hirao, Y; Ijuin, M; Ikuma, S; Ohara, S; Ohishi, H; Okajima, E; Shiomi, T, 1981
)
0.26
"Highly invasive carcinomas of the urinary bladder were induced in male C57BL/6 X DBA/2 F1 (hereafter called B6D2F1) mice by gastric intubation of N-butyl-(4-hydroxybutyl)nitrosamine (OH-BBN) using a quantitative dosing schedule."( N-butyl-N-(4-hydroxybutyl)nitrosamine-induced urinary bladder cancer in C57BL/6 X DBA/2 F1 mice as a useful model for study of chemoprevention of cancer with retinoids.
Becci, PJ; Brown, CC; Moon, RC; Sporn, MB; Strum, JM; Thompson, HJ, 1981
)
0.26
" Oltipraz was fed in the diet from one week prior to OH-BBN dosing until sacrifice, six months later."( Chemoprevention of OH-BBN-induced bladder cancer in mice by oltipraz, alone and in combination with 4-HPR and DFMO.
Detrisac, CJ; Kelloff, GJ; Moon, RC; Sigman, CC; Steele, VE; Thomas, CF,
)
0.13
" dosed isothiocyanate."( Inhibition of urinary bladder carcinogenesis by broccoli sprouts.
Davis, W; Fahey, JW; Lister, C; Mhawech-Fauceglia, P; Munday, CM; Munday, JS; Munday, R; Paonessa, JD; Tang, L; Wilson, P; Zhang, Y, 2008
)
0.35
" Rats were dosed daily with NPX (40 mg/kg body weight/day, gavage) or with the proton pump inhibitor omeprazole (4."( Prevention of chemically induced urinary bladder cancers by naproxen: protocols to reduce gastric toxicity in humans do not alter preventive efficacy.
Bode, A; Boring, DL; Grubbs, CJ; Juliana, MM; Lubet, RA; Minasian, L; Scheiman, JM; Steele, VE; White, J, 2015
)
0.42
"5% groups of male and female rats in a dose-response manner."( Promotion effects of acetoaceto-o-toluidide on N-butyl-N-(4-hydroxybutyl)nitrosamine-induced bladder carcinogenesis in rats.
Fujioka, M; Gi, M; Kakehashi, A; Koda, S; Nakatani, T; Okuno, T; Suda, M; Suzuki, S; Wanibuchi, H; Yanagiba, Y; Yukimatsu, N, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
carcinogenic agentA role played by a chemical compound which is known to induce a process of carcinogenesis by corrupting normal cellular pathways, leading to the acquistion of tumoral capabilities.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
nitrosamineN-Nitroso amines, compounds of the structure R2NNO. Compounds RNHNO are not ordinarily isolable, but they, too, are nitrosamines. The name is a contraction of N-nitrosoamine and, as such, does not require the N locant.
primary alcoholA primary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has either three hydrogen atoms attached to it or only one other carbon atom and two hydrogen atoms attached to it.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (3)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
estrogen nuclear receptor alphaHomo sapiens (human)Potency37.04180.000229.305416,493.5996AID1259244; AID743075
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency68.58960.001557.789015,848.9004AID1259244
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency68.58960.001551.739315,848.9004AID1259244
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID226732The compound was modelled in silico for carcinogenic potency; + = Carcinogen1982Journal of medicinal chemistry, Jul, Volume: 25, Issue:7
Computer-assisted studies of structure-activity relationships of N-nitroso compounds using pattern recognition.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (543)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990223 (41.07)18.7374
1990's162 (29.83)18.2507
2000's73 (13.44)29.6817
2010's72 (13.26)24.3611
2020's13 (2.39)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 8.09

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index8.09 (24.57)
Research Supply Index6.33 (2.92)
Research Growth Index4.42 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (8.09)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.18%)5.53%
Reviews12 (2.15%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other544 (97.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]